DomÃnguez-Prieto, V.; León-Arellano, M.; Olivera-Salazar, R.; Vega-Clemente, L.; Caramés, C.; Ruiz-Hispán, E.; Fuentes-Mateos, R.; Rosero-RodrÃguez, D.; Guadalajara, H.; GarcÃa-Arranz, M.;
et al. Pre-Treatment SEPTIN9 Gene Methylation Ratio Predicts Tumor Response to Total Neoadjuvant Therapy in Patients with Locally Advanced Rectal Cancer. Cancers 2025, 17, 965.
https://doi.org/10.3390/cancers17060965
AMA Style
DomÃnguez-Prieto V, León-Arellano M, Olivera-Salazar R, Vega-Clemente L, Caramés C, Ruiz-Hispán E, Fuentes-Mateos R, Rosero-RodrÃguez D, Guadalajara H, GarcÃa-Arranz M,
et al. Pre-Treatment SEPTIN9 Gene Methylation Ratio Predicts Tumor Response to Total Neoadjuvant Therapy in Patients with Locally Advanced Rectal Cancer. Cancers. 2025; 17(6):965.
https://doi.org/10.3390/cancers17060965
Chicago/Turabian Style
DomÃnguez-Prieto, VÃctor, Miguel León-Arellano, RocÃo Olivera-Salazar, Luz Vega-Clemente, Cristina Caramés, Eva Ruiz-Hispán, Raquel Fuentes-Mateos, Diana Rosero-RodrÃguez, Héctor Guadalajara, Mariano GarcÃa-Arranz,
and et al. 2025. "Pre-Treatment SEPTIN9 Gene Methylation Ratio Predicts Tumor Response to Total Neoadjuvant Therapy in Patients with Locally Advanced Rectal Cancer" Cancers 17, no. 6: 965.
https://doi.org/10.3390/cancers17060965
APA Style
DomÃnguez-Prieto, V., León-Arellano, M., Olivera-Salazar, R., Vega-Clemente, L., Caramés, C., Ruiz-Hispán, E., Fuentes-Mateos, R., Rosero-RodrÃguez, D., Guadalajara, H., GarcÃa-Arranz, M., & GarcÃa-Olmo, D.
(2025). Pre-Treatment SEPTIN9 Gene Methylation Ratio Predicts Tumor Response to Total Neoadjuvant Therapy in Patients with Locally Advanced Rectal Cancer. Cancers, 17(6), 965.
https://doi.org/10.3390/cancers17060965
